← Back to patent-cliff list
Lidocaine patch transdermal (D. Western Therapeutics Institute/MEDRx)
Tier C — Watch / tradeLidocaine patch transdermal (D. Western Therapeutics Institute/MEDRx)
D. Western Therapeutics Institute
Originator
2025
First approval
-
Expiry (public)
No sales data
Peak sales
Small molecule
Type
Targets：SCNA
Brand：Bondlido, Lydolyte
Indications (approved)：Postherpetic neuralgia
Regional status
US
Approved
2025-09-24
EU
-
China
-
Japan
-
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of Lidocaine patch transdermal (D. Western Therapeutics Institute/MEDRx)?
Approved indications include: Postherpetic neuralgia.
When does the Lidocaine patch transdermal (D. Western Therapeutics Institute/MEDRx) patent expire?
No public expiry year is available for Lidocaine patch transdermal (D. Western Therapeutics Institute/MEDRx) yet; this page updates once verified.
How do I get a quote for Lidocaine patch transdermal (D. Western Therapeutics Institute/MEDRx) intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-10-01